Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TERT | O14746 | 5/20 | 0.57 |
| ▸ | TOP1 | P11387 | 4/20 | 0.55 |
| ▸ | CYCS | P99999 | 3/20 | 0.54 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.53 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17967720 | 0.98 | TERT (0.55) | TERTTOP1CYCSENPP2ABCG2 | |
| SCHEMBL29196451 | 0.98 | TERT (0.55) | TERTTOP1CYCSENPP2ABCG2 | |
| Hydrochloric Acid SCHEMBL29838107 | 0.98 | TERT (0.55) | TERTTOP1CYCSENPP2ABCG2 | |
| Hydrochloric Acid SCHEMBL3287053 | 0.98 | TERT (0.55) | TERTTOP1CYCSENPP2ABCG2 | |
| Bromide SCHEMBL4139455 | 0.98 | TERT (0.55) | TERTTOP1CYCSENPP2ABCG2 | |
| SCHEMBL29349689 | 0.98 | TERT (0.59) | TERTTOP1CYCSENPP2ABCG2 | |
| SCHEMBL4140450 | 0.94 | TERT (0.51) | TERTTOP1CYCSENPP2ABCG2 | |
| SCHEMBL30853260 | 0.94 | TERT (0.51) | TERTTOP1CYCSENPP2ABCG2 | |
| SCHEMBL5706257 | 0.94 | TERT (0.51) | TERTTOP1CYCSENPP2ABCG2 | |
| SCHEMBL18155364 | 0.91 | TOP1 (0.64) | TERTTOP1CYCSENPP2ABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1798600-B1 | Use of a porhine agent for reducing the potential of ghosting in an imaging member | XEROX CORP (US) | 2012-10-10 | — | — | EP | claimed |
| US-8133739-B2 | Reagent for measurement of concentration of lead, and method for measurement of concentration of lead | KOWA CO., LTD. (JP) | 2012-03-13 | — | — | US | claimed |
| EP-2135313-B1 | HIGH PERFORMANCE, HIGH DURABILITY NON-PRECIOUS METAL FUEL CELL CATALYSTS | 3M INNOVATIVE PROPERTIES CO (US) | 2011-09-14 | — | — | EP | claimed |
| EP-0743574-B1 | Migration imaging members | XEROX CORP (US) | 2000-12-27 | — | — | EP | claimed |
| EP-0743573-B1 | Method for obtaining image contrast migration imaging members | XEROX CORP (US) | 2000-09-06 | — | — | EP | claimed |
| US-5702804-A | Recording sheets | XEROX CORPORATION (US) | 1997-12-30 | — | — | US | claimed |
| US-5541633-A | Ink jet printing of concealed images on carbonless paper | XEROX CORPORATION (US) | 1996-07-30 | — | — | US | claimed |
| US-5286286-A | Containing diethylene glycol monobutyl ether, glycerol, and a dansyl or porphyrin chromophores | XEROX CORPORATION (US) | 1994-02-15 | — | — | US | claimed |
| US-5256193-A | Porphyrin chromophore and dendrimer ink composition | XEROX CORPORATION (US) | 1993-10-26 | — | — | US | claimed |
| US-20240000084-A1 | ANTIPATHOGENIC AGENT, ANTIBACTERIAL AGENT, ANTIVIRAL AGENT, PATHOGEN DISPOSAL DEVICE, ANTIPATHOGENIC AGENT PRODUCTION METHOD, ANTIBACTERIAL TREATMENT METHOD, VIRUS INACTIVATION METHOD, AND PATHOGEN DISPOSAL METHOD | ACENET INC. (JP) | 2024-01-04 | — | — | US | disclosed |
| WO-2023190598-A1 | COMPOSITION | アース製薬株式会社 | 2023-10-05 | — | — | WO | disclosed |
| US-20230263710-A1 | ORAL CARE AGENT | OSAKA UNIVERSITY (JP) | 2023-08-24 | — | — | US | disclosed |
| US-20230248805-A1 | INHIBITION OF ENDOSOMAL TOLL-LIKE RECEPTOR ACTIVATION | DUKE UNIVERSITY | 2023-08-10 | — | — | US | disclosed |
| US-20230181628-A1 | EPITHELIAL CANCER THERAPEUTIC AGENT | OSAKA UNIVERSITY (JP) | 2023-06-15 | — | — | US | disclosed |
| US-5709737-A | AQUEOUS LIQUID VEHICLE, COLORANT, ALCOHOL ADDITIVE; SUITABLE FOR MICROWAVE DRYING PROCESSES | XEROX CORPORATION (US) | 1998-01-20 | — | — | US | disclosed |
| US-5541633-A | Ink jet printing of concealed images on carbonless paper | XEROX CORPORATION (US) | 1996-07-30 | — | — | US | disclosed |
| US-5286286-A | Containing diethylene glycol monobutyl ether, glycerol, and a dansyl or porphyrin chromophores | XEROX CORPORATION (US) | 1994-02-15 | — | — | US | disclosed |
| US-5271764-A | Ink compositions | XEROX CORPORATION (US) | 1993-12-21 | — | — | US | disclosed |
| US-5256193-A | Porphyrin chromophore and dendrimer ink composition | XEROX CORPORATION (US) | 1993-10-26 | — | — | US | disclosed |
| WO-1993000815-A1 | POLYMER COMPOSITIONS | COURTAULDS PLC (GB) | 1993-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230263710-A1 | ORAL CARE AGENT | TAS2R39, TAS2R40, TAS2R45 | TERT 665/4885TOP1 3027/4885CYCS 3634/4885 |
| US-20230181628-A1 | EPITHELIAL CANCER THERAPEUTIC AGENT | EPCAM, EGFR, MUC1 | TERT 2374/4885TOP1 961/4885CYCS 4782/4885 |
| US-20240000084-A1 | ANTIPATHOGENIC AGENT, ANTIBACTERIAL AGENT, ANTIVIRAL AGENT, PATHOGEN DISPOSAL DEVICE, ANTIPATHOGENIC AGENT PRODUCTION METHOD, ANTIBACTERIAL TREATMENT METHOD, VIRUS INACTIVATION METHOD, AND PATHOGEN DISPOSAL METHOD | EIF2AK2, HAO2, ZC3HAV1 | TERT 2605/4885TOP1 1139/4885CYCS 4032/4885 |
| US-20230248805-A1 | INHIBITION OF ENDOSOMAL TOLL-LIKE RECEPTOR ACTIVATION | TLR3, TLR9, TLR1 | TERT 4391/4885TOP1 3591/4885CYCS 4825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.